Cancer Technologies are employed to develop new and advanced technologies for a broad range of cancer applications, especially early cancer detection, minimally invasive surgery, and targeted therapy. Specific topics include the development of new contrast agents for molecular and cellular cancer imaging; new nanoparticle drugs for targeted cancer therapy; advanced instrumentation for minimally invasive and robotic cancer surgery; engineering of the immune system and stem cells for cancer immunotherapy; and software tools and algorithms for cancer biomarker discovery and bioinformatics. A particular strength of the GT/Emory program is the development and translation of bioconjugated nanoparticles (such as semiconductor quantum dots, plasmonic nanostructures, molecular beacons, and liposomes) for in-vivo cancer imaging, molecular profiling, image-guided surgery, and personalized therapy. This research is carried out in close collaboration with the Winship Cancer Institute (WCI) of Emory University, and spans many types of human tumors including breast, lung, pancreatic, ovarian, glioblastoma (brain tumor), head and neck, colon and prostate cancers. Being intrinsically interdisciplinary and translational, this focus area addresses a major need in human health, and provides excellent opportunities for aspiring undergraduates, graduates, and postdoctoral fellows.